Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.

Experimental eye research - 1 Apr 2024

Karaosmanoglu Beren, Imren Gozde, Utine Eda, Taylan Sekeroglu Hande, Taskiran Ekim Z

Abstract excerpt

Retinal dystrophies are a common health problem worldwide that are currently incurable due to the inability of retinal cells to regenerate. Inherited retinal diseases (IRDs) are a diverse group of disorders characterized by progressive vision loss caused by photoreceptor cell dysfunction. The eye has always been an attractive organ for the development of novel therapies due to its independent access to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Bestrophins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BEST1 gene

Share to Oligonucleotides, Antisense

Share to Retinal Diseases

Share to RNA, Messenger

Source

Identifiers

PMID: 38369231
DOI: 10.1016/j.exer.2024.109833

Genes

BEST1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.PMID 38369231Read ↗

Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.Semantic proximity Read ↗

Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes.Semantic proximity Read ↗

Development and Use of Cellular Systems to Assess and Correct Splicing Defects.Semantic proximity Read ↗

Gene Therapy for Inherited Retinal Diseases: From Laboratory Bench to Patient Bedside and BeyondSemantic proximity Read ↗

RNA therapeutics for retinal diseasesSemantic proximity Read ↗

Antisense oligonucleotide therapy for the common Stargardt disease type 1-causing variant in <i>ABCA4</i>Semantic proximity Read ↗

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnologySemantic proximity Read ↗

Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.Semantic proximity Read ↗

Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.Semantic proximity Read ↗

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular DystrophySemantic proximity Read ↗

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development TherapeuticsSemantic proximity Read ↗

Antisense oligonucleotides and their applications in rare neurological diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.